Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

TRENDING
AI Platform Developer Cloudwise Raises $150 Million
Chinese Tesla Challenger Nio Begins Shipping SUVs to Norway
Xiaomi Leads India’s Smartphone Market With 29% Share
LATEST
AI Platform Developer Cloudwise Raises $150 Million
Chinese Tesla Challenger Nio Begins Shipping SUVs to Norway
Xiaomi Leads India’s Smartphone Market With 29% Share
Alibaba Targets Fresh Graduates to Stay Competitive in Tech Market
Foxconn Talks Electric-Vehicle Motor Venture With Japan’s Nidec
Volvo Cars Wants Full Control Over Its China Ventures as Beijing Mulls Lifting Foreign Ownership Cap
Sherpa Healthcare Partners Launches Chinese Medical Tech Fund
XYZ Robotics Capitalizes on Tech Investment Boom With New Funding
DeepRoute.ai Self-Driving Taxis Hit Shenzhen Roads
Trending in China: #MeToo Movement Resurfaces as Singer Accused of Rape
Two Tencent Games Account for a Third of World’s Top 10 Sales
Baidu Expands Robotaxi Pilot Program to Guangzhou
Joining Convoy of Peers, WeRide Sets Sights on Autonomous Trucking
Ant-Backed Digital Payments Firm Paytm Files for $2.2 Billion IPO in Mumbai
Autonomous Delivery Vehicle Specialist White Rhino Closes $10 Million Funding Round
Peking University Jumps on the Microchip Education Bandwagon
TuSimple, AEye to Develop Lidar Sensors for Autonomous Trucks
Beyond Meat Deepens Push Into China With Launch of JD.com Store
Closing In on Samsung, Xiaomi Dethrones Apple to Become World’s No. 2 Smartphone Seller
Alibaba to Lead $257 Million Fund to Support Tech Startups in China’s Greater Bay Area
Chinese DNA Sequencing Firm BGI Faces Legal Battle with Illumina

By Wang Luyao and Han Wei / May 24, 2019 02:59 AM / Business & Tech

Photo: VCG

Photo: VCG

Chinese genomics giant BGI Group said it is prepared in the face of rising legal disputes in Europe and may resort to counterclaims to fight patent infringement allegations.

BGI is “actively responding to recent patent disputes and will take corresponding legal actions,” BGI said in a statement to Caixin Thursday, adding that it “will not rule out the use of legal weapons such as counterclaims to protect its legal rights.”

BGI’s subsidiary BGI Europe was sued by Illumina Inc. in Denmark on alleged patent infringement last week. The complaint alleged BGI's sequencing products and related sequencing chemistry reagents infringe on Illumina's European patent.

The case followed another infringement suit filed by Illumina in Germany against another BGI subsidiary, Latvia MGI Tech, in March.

In the statement, BGI said it is confident in its own technology, which cost billions of yuan to develop and “broke the market monopoly in the upstream genome sequencing market.”

When interviewed by Caixin earlier this month on whether Illumina will file more suits against BGI outside Europe, the company’s Chief Commercial Officer Mark Van Oene said Illumina will continue pursuing patent protection, without elaborating.

Established in 1999, BGI was a client of Illumina’s sequencing equipment but has started to develop its own devices after purchasing U.S. genomics company Complete Genomics in 2012.

Related: BGI Genomics’ Profits Slip As Questions Linger About Its Services


Share this article
Open WeChat and scan the QR code